8-K: Nordson Reports Strong Q3, Boosts Share Buyback

Nordson Corporation reported robust third-quarter fiscal 2025 results, exceeding expectations with double-digit growth in sales, adjusted EPS, and EBITDA, while authorizing an additional $500 million in share repurchases.

Summary

• Sales for the third quarter of fiscal 2025 reached $742 million, marking a 12% increase year-over-year from $662 million.
• Adjusted earnings per diluted share rose by 13% year-over-year to $2.73, compared to $2.41 in the prior year.
• EBITDA increased by 15% to $239 million, representing 32% of sales, up from $208 million (31% of sales) in the prior year.
• Free cash flow conversion was exceptionally strong at 180% of net income.
• The Board of Directors authorized an additional $500 million for share repurchases, bringing the total available authorization to approximately $793 million.
• The Advanced Technology Solutions segment demonstrated significant organic sales growth of 15%, driven by electronics dispense product lines.
• The Medical and Fluid Solutions segment saw sales increase by 32%, primarily due to a 31% acquisition impact, with organic sales flat but up 4% excluding the pending divestiture.
• Industrial Precision Solutions experienced a 2% organic sales decrease, offset by favorable currency translation, resulting in a 1% overall sales increase.
• Full year fiscal 2025 sales are now tracking slightly below the mid-point of original guidance, while full year adjusted earnings per share are tracking slightly above the mid-point.

Sentiment

Score: 8

Explanation: The filing indicates strong financial performance in Q3, with significant growth in key metrics like sales, adjusted EPS, and EBITDA. The substantial share repurchase authorization and excellent free cash flow conversion are highly positive. While there's a slight organic sales decline in one segment and full-year sales tracking slightly below the midpoint, the overall affirmation of guidance and slight upward revision for adjusted EPS outlook suggest a very positive operational and financial trajectory.

Positives

• Strong overall sales growth of 12% year-over-year to $742 million.
• Adjusted earnings per diluted share increased by 13% to $2.73, indicating strong profitability.
• EBITDA grew by 15% to $239 million, with an improved margin of 32% of sales.
• Exceptional free cash flow conversion of 180% of net income, demonstrating efficient cash generation.
• Board authorized an additional $500 million for share repurchases, signaling confidence and commitment to shareholder returns, bringing total authorization to $793 million.
• Advanced Technology Solutions segment delivered robust 15% organic sales growth.
• Successful integration and contribution from the Atrion acquisition, exceeding expectations in its first year.
• Maintained a strong balance sheet and used cash flow to reduce debt, repurchase shares, and return dividends.

Negatives

• Industrial Precision Solutions segment experienced a 2% organic sales decrease, driven by weaker systems demand in polymer processing.
• Backlog is down approximately 5% sequentially following a strong third quarter.
• Full year sales are now tracking slightly below the mid-point of original guidance.

Risks

• U.S. and international economic and political conditions.
• Financial and market conditions.
• Currency exchange rates and devaluations.
• Ability to successfully integrate possible acquisitions.
• Ability to successfully divest or dispose of businesses that do not fit the strategic plan.
• Effects of changes in U.S. trade policy and trade agreements, including tariffs.
• Effects of changes in tax law.
• Possible effects of events beyond control, such as political unrest (including conflicts in Europe and the Middle East), acts of terror, natural disasters, and pandemics.

Future Outlook

Management affirmed full year fiscal 2025 sales guidance and earnings expectations. Full year sales are now tracking slightly below the mid-point of original guidance, while full year adjusted earnings per share are tracking slightly above the mid-point. This outlook assumes the completion of the pending divestiture of the medical contract manufacturing business in the fourth quarter. The company expects to continue driving organic growth through new product vitality and operational excellence.

Management Comments

• "The Nordson team responded effectively to dynamic demand conditions in key end markets and delivered on its promises, realizing solid year-over-year organic growth in the quarter."
• "In particular, the Advanced Technology Solutions segment delivered 15% organic sales growth."
• "Operational excellence drove strong profit performance, increasing adjusted earnings per share by 13% and EBITDA by 15%."
• "In this final full quarter of Atrions first year acquisition performance, our new employees again exceeded expectations and contributed to both sales and earnings results."
• "Also this quarter, we maintained a strong balance sheet, delivering cash flow conversion of 180% of net income that we used to reduce debt, repurchase shares and return dividends to shareholders, while continuing to invest in the company."
• "Following a strong third quarter, I am pleased that we are able to affirm our full year sales guidance and earnings expectations."
• "NBS Next is driving organic growth by enhancing our new product vitality, best-in-class quality and delivery, while also empowering our teams to respond quickly to changing customer demand."
• "Through our close-to-customer business model, diverse product portfolio and in-region, for-region manufacturing strategy, we have continuously demonstrated resilience and the ability to deliver solid growth and best-in-class profitability in varying market scenarios."

Industry Context

Nordson's performance reflects a mixed demand environment across its diverse end markets. While the Advanced Technology Solutions segment, serving electronics, showed robust growth, the Industrial Precision Solutions segment faced headwinds in polymer processing. The company's ability to leverage acquisitions and operational excellence to drive profit growth and strong cash flow, even with some organic softness in certain areas, demonstrates resilience. The pending divestiture of the medical contract manufacturing business aligns with a trend of companies streamlining portfolios to focus on core, higher-growth areas.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct benchmarking against industry peers.
• Nordson's reported EBITDA margin of 32% and free cash flow conversion of 180% are indicative of strong operational efficiency and cash generation, which typically compare favorably to industry averages for precision technology and industrial manufacturing companies.
• The company's 'close-to-customer business model, diverse product portfolio and in-region, for-region manufacturing strategy' are described as drivers of resilience and best-in-class profitability, suggesting a competitive advantage in varying market scenarios.

Corporate Governance

Stakeholder Impact

• Shareholders: Directly benefit from the increased share repurchase authorization, which can enhance shareholder value by reducing outstanding shares and potentially boosting EPS. Dividends are also being returned to shareholders.
• Creditors: The company used cash flow to reduce debt, which is positive for creditors as it strengthens the balance sheet and reduces financial risk.
• Customers: Implied benefit from the 'NBS Next' initiative driving new product vitality, best-in-class quality and delivery, and a 'close-to-customer business model' enabling quick response to changing demand.

Next Steps

• Nordson management will provide additional commentary on third quarter fiscal 2025 results and outlook during a webcast on Thursday, August 21, 2025, at 8:30 a.m. eastern time.
• Completion of the pending divestiture of the medical contract manufacturing business is assumed in the fourth quarter of fiscal 2025.

Key Dates

Recommendation

Nordson's Q3 fiscal 2025 results demonstrate strong operational execution with double-digit growth in sales, adjusted EPS, and EBITDA, coupled with exceptional free cash flow generation. The significant increase in the share repurchase authorization signals strong management confidence and a commitment to shareholder returns. While there are minor headwinds in one segment and the full-year sales outlook is slightly tempered, the overall affirmation of guidance and the slight upward revision for adjusted EPS indicate a resilient business model and effective strategic management. The pending divestiture of the medical contract manufacturing business could further streamline operations. These factors collectively present a compelling investment case for a seasoned investor seeking a stable, profitable company with a clear strategy for growth and shareholder value creation.

Keywords

Nordson, NDSN, SEC filing, 8-K, earnings, financial results, Q3 2025, sales, EPS, EBITDA, share repurchase, cash flow, Advanced Technology Solutions, Medical and Fluid Solutions, Industrial Precision Solutions, corporate governance, precision technology